BO-112

Phase 2Small molecule

HHighlight Therapeutics

BO-112 is one of 17 small molecule programs targeting Basal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Basal Cell CarcinomaActive, not recruiting

Basal Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Basal Cell Carcinoma

#DrugCompanyPhaseTrials

Erivedge

Roche

Approved

21 2

Aldara

BBausch Health Americas, Inc.

Approved

7 3

Levulan

Sun Pharmaceutical Industries, Inc.

Adriamycin

Visudyne

BBausch Health Americas, Inc.

Approved

—6

Retin-a

VValeant Pharmaceuticals

Adrucil

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Libtayo

4 10

Opdivo

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Active, not recruiting

Basal Cell Carcinoma

NCT06422936

Clinical

Trials by Indication[1]

Metastasis1 trial

Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis

Terminated·HHighlight Therapeutics·Phase 2·NCT04508140·18 enrolled

Melanoma1 trial

BO-112 With Pembrolizumab in Unresectable Malignant Melanoma

Completed·HHighlight Therapeutics·Phase 2·NCT04570332·42 enrolled

Basal Cell Carcinoma1 trial

SPOTLIGHT 204: A Multicenter, Phase 2b, Open-label, Non-randomized, Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of Intra-lesional BO-112 in Patients With Resectable Primary Low and High Risk Basal Cell Carcinoma

Active, not recruiting·HHighlight Therapeutics·Phase 2·NCT06422936·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BO-112. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BO-112 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BO-112. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Highlight Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHighlight Therapeutics

BO-112

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Metastasis1 trial

Melanoma1 trial

Basal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News